{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:16:24Z","timestamp":1789614984422,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.intimp.2020.106688","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T05:31:33Z","timestamp":1591507893000},"page":"106688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial"],"prefix":"10.1016","volume":"85","author":[{"given":"Farzaneh","family":"Dastan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Alireza","family":"Nadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Saffaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Marjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Moniri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Jamaati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed MohammadReza","family":"Hashemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvaneh","family":"Baghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Abedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Varahram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Yousefian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Tabarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106688_b0005","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2020.106688_b0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","article-title":"Potential interventions for novel coronavirus in China: A systematic review","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2020.106688_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105945","article-title":"Aminoquinolines against coronavirus disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine","author":"Sahraei","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.106688_b0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Seminars Immunopathol."},{"key":"10.1016\/j.intimp.2020.106688_b0025","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2020.106688_b0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Gonz\u00e1lez-Navajas","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106688_b0035","doi-asserted-by":"crossref","first-page":"71249","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.intimp.2020.106688_b0040","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1128\/JVI.79.15.9608-9617.2005","article-title":"Gene expression and antiviral activity of alpha\/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells","volume":"79","author":"Osterlund","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.106688_b0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: Success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2020.106688_b0050","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.intimp.2020.106688_b0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3201\/eid1002.030482","article-title":"Interferon-beta 1a and SARS coronavirus replication","volume":"10","author":"Hensley","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.106688_b0060","doi-asserted-by":"crossref","unstructured":"V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K.W. Chu et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 25 (2020) 2000045.","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045"},{"key":"10.1016\/j.intimp.2020.106688_b0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2567.2007.02719.x","article-title":"Immunological decision-making: how does the immune system decide to mount a helper T-cell response?","volume":"123","author":"Kaiko","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2020.106688_b0070","doi-asserted-by":"crossref","first-page":"5370706","DOI":"10.1155\/2019\/5370706","article-title":"Class I Molecules exacerbate viral infection by disrupting type I. interferon signaling","volume":"2019","author":"Xia","year":"2019","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.intimp.2020.106688_b0075","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fimmu.2017.00304","article-title":"Type I Interferons and Natural Killer Cell Regulation in Cancer","volume":"8","author":"M\u00fcller","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2020.106688_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2016.01.001","article-title":"Type I interferons in viral control and immune regulation","volume":"16","author":"Teijaro","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.intimp.2020.106688_b0085","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/jir.2014.0227","article-title":"Disease-promoting effects of type I interferons in viral, bacterial, and coinfections","volume":"35","author":"Davidson","year":"2015","journal-title":"J. Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res."},{"key":"10.1016\/j.intimp.2020.106688_b0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijid.2013.12.003","article-title":"Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study","volume":"20","author":"Al-Tawfiq","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.106688_b0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S2213-2600(13)70259-5","article-title":"The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study","volume":"2","author":"Bellingan","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.intimp.2020.106688_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.106688_b0105","doi-asserted-by":"crossref","unstructured":"J. Hadjadj, N. Yatim, L. Barnabei, A. Corneau, J. Boussier, H. Pere, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients, medRxiv. 2020: 2020.04.19.20068015.","DOI":"10.1101\/2020.04.19.20068015"},{"key":"10.1016\/j.intimp.2020.106688_b0110","article-title":"A fourteen-day experience with coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS): an Iranian treatment protocol","author":"Jamaati","year":"2020","journal-title":"Iran. J. Pharmaceut. Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920312893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920312893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:17:46Z","timestamp":1761585466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920312893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":22,"alternative-id":["S1567576920312893"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106688","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106688"}}